Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

KYOWA HAKKO KIRIN CO LTD (4151)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Latest news on KYOWA HAKKO KIRIN CO LTD
04/19KYOWA HAKKO KIRIN : New Dermatitis Study Findings Have Been Reported by Investig..
AQ
04/18Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita
AQ
04/16Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimila..
AQ
04/12KYOWA HAKKO KIRIN : Studies from Kyowa Hakko Kirin Co in the Area of Gastroenter..
AQ
04/12Fujifilm Kyowa Kirin Biologics Partners With Mylan to Commercialize Biosimila..
AQ
04/12Fujifilm Kyowa Kirin Biologics Partners With Mylan to Commercialize
AQ
04/05KYOWA HAKKO KIRIN : Data on Aldehyde Oxidoreductases Described by Researchers at..
AQ
04/04KYOWA HAKKO KIRIN : Matters concerning controlling shareholders
AQ
04/03Reata Announces Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designati..
AQ
04/03Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Desi..
AQ
04/02KYOWA HAKKO KIRIN : Bardoxolone Methyl Designated for the Treatment of Diabetic ..
AQ
03/27KYOWA HAKKO KIRIN : and BioWa Obtain Successful Settlement of United States Pate..
AQ
03/23KYOWA HAKKO KIRIN CO LTD : Proxy Statments
CO
03/22Aplastic Anemia (AA)- Market Is Expected to Grow with Upcoming Therapies
AQ
03/15Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin
AQ
03/02KYOWA HAKKO KIRIN CO LTD : Mixed general shareholder meeting
CO
03/01KYOWA HAKKO KIRIN : Studies from Kyowa Hakko Kirin Co Provide New Data on Aldehy..
AQ
02/26Kyowa Kirin and Ultragenyx Announce Crysvita Receives Conditional Marketing A..
AQ
02/26XLH therapy burosumab gains EU approval
AQ
02/23KYOWA HAKKO KIRIN : Notice Concerning Change of Certified Public Accountant, etc
AQ
02/23KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for stock compensa..
AQ
01/31KYOWA HAKKO KIRIN : Announces Reorganization of Research and Development Divisio..
AQ
01/31Kyowa Hakko Bio Announces a Change to the Representative Director
AQ
01/31KYOWA HAKKO KIRIN : Announces the Establishment of a Regional Headquarters Funct..
AQ
01/19Patent Issued for Orally Disintegrating Tablet (USPTO 9861577)
AQ
01/09KYOWA KIRIN : Creating opportunities from challenges
AQ
01/08KYOWA HAKKO KIRIN : Notice Concerning Completion of Consolidated Subsidiary Shar..
AQ
01/04KYOWA HAKKO KIRIN : Findings from Kyowa Hakko Kirin Co Reveals New Findings on D..
AQ
2017KYOWA HAKKO KIRIN CO LTD : Financial report
CO
2017KYOWA HAKKO KIRIN CO LTD : Annual Report
CO
2017KYOWA HAKKO KIRIN : Announces Changes in the Representative Directors
AQ
2017BIOCENTURY - MANAGEMENT TRACKS : Vivus, Peregrine
AQ
2017KYOWA HAKKO KIRIN CO LTD : Ex-dividend day for for final dividend
FA
2017KYOWA HAKKO KIRIN : EMA committee recommends marketing approval for Burosumab to..
AQ
2017Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
AQ
2017Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
AQ
2017KYOWA HAKKO KIRIN : Announces Results of Phase 3 Clinical Study of Mogamulizumab..
AQ
2017KYOWA HAKKO KIRIN : Announces Results of Phase 3 Clinical Study of Mogamulizumab..
AQ
2017KYOWA HAKKO KIRIN : Poteligeo meets in Phase III for CTCL
AQ
2017REATA PHARMACEUTICALS, INC. (NASDAQ : RETA) Files An 8-K Entry into a Material D..
AQ
2017KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
AQ
2017Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
AQ
2017Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
AQ
2017KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data fr..
PU
2017KYOWA HAKKO KIRIN : Submits the Partial Change Approval Application of Mogamuliz..
AQ
2017KYOWA HAKKO KIRIN : Reports Outline Antisense Oligonucleotides Study Results fro..
AQ
2017Ardelyx, Kyowa Hakko Kirin ink licensing pact for tenapanor for cardiorenal d..
AQ
2017KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
AQ
2017KYOWA HAKKO KIRIN : mogamulizumab gets Priority Review for CTCL
AQ
2017KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
BU
2017KYOWA HAKKO KIRIN : Ardelyx and Kyowa Hakko Kirin Announce License Agreement for..
PU
2017KYOWA HAKKO KIRIN : "Protein Production Method" in Patent Application Approval P..
AQ
2017KYOWA HAKKO KIRIN : Research Data from Kyowa Hakko Kirin Co Update Understanding..
AQ
2017KYOWA HAKKO KIRIN : Presented Results of Japan Phase III Clinical Study of Evoca..
AQ
2017KYOWA HAKKO KIRIN : Presented Results of Phase II Study of Bardoxolone Methyl in..
AQ
2017Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
AQ
2017KYOWA HAKKO KIRIN : Presented Results of Phase II Study of Bardoxolone Methyl in..
PU
2017KYOWA HAKKO KIRIN : Presented Results of Japan Phase III Clinical Study of Evoca..
PU
2017KYOWA HAKKO KIRIN : Concerning an Announcement by Kirin Holdings
AQ
2017Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
AQ
2017KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently ..
PU
2017KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
AQ
2017KYOWA HAKKO KIRIN : Concerning an Announcement by Kirin Holdings Company, Limite..
PU
2017KYOWA HAKKO KIRIN : Announces Initiation of the Phase III Clinical Study of KHK7..
PU
2017KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
PU
2017KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
BU
2017KYOWA HAKKO KIRIN : Matters Concerning Voluntary Adoption ofInternational Financ..
PU
2017KYOWA HAKKO KIRIN : Announces the Intent to File Istradefylline for Parkinson's ..
AQ
2017KYOWA HAKKO KIRIN : Announces the Intent to File Istradefylline (KW-6002) for Pa..
PU
2017Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for t..
AQ
2017Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review ..
AQ
2017Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review ..
AQ
2017KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and..
PU
2017Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197
AQ
2017Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for t..
AQ
1  2  3  4Next
Financials ( JPY)
Sales 2018 346 B
EBIT 2018 -
Net income 2018 44 805 M
Finance 2018 44 348 M
Yield 2018 1,23%
P/E ratio 2018 27,30
P/E ratio 2019 27,82
EV / Sales 2018 3,83x
EV / Sales 2019 3,54x
Capitalization 1 368 B
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 522  JPY
Spread / Average Target 6,3%
EPS Revisions
Managers
NameTitle
Nobuo Hanai Chairman & Chief Executive Officer
Masashi Miyamoto President, COO & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD6.80%12 707
ABBVIE-4.25%146 927
MERCK KGAA-8.61%13 024
JAZZ PHARMACEUTICALS PLC17.30%9 446
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD35.57%8 212
CONVATEC GROUP5.60%5 968